Quote | Lantern Pharma Inc. (NASDAQ:LTRN)
Last: | $4.38 |
---|---|
Change Percent: | 0.93% |
Open: | $4.25 |
Close: | $4.38 |
High: | $4.57 |
Low: | $4.25 |
Volume: | 17,695 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Lantern Pharma Inc. (NASDAQ:LTRN)
LP-284 is currently in a Phase 1 clinical trial, having been developed with guidance from Lantern’s AI platform, RADR ® , as a potential therapy for relapsed or refractory non-Hodgkin’s lymphoma and certain genomically defined sarcomas. LP-284 is the third molecule brou...
2024-05-24 16:39:53 ET More on Lantern Pharma Lantern Pharma Inc. (LTRN) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Lantern Pharma Historical earnings data for Lantern Pharma Financial information for Lantern Pharma Read...
Message Board Posts | Lantern Pharma Inc. (NASDAQ:LTRN)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
LP-284 is currently in a Phase 1 clinical trial, having been developed with guidance from Lantern’s AI platform, RADR ® , as a potential therapy for relapsed or refractory non-Hodgkin’s lymphoma and certain genomically defined sarcomas. LP-284 is the third molecule brou...
Active clinical trials across three AI-guided drug candidates with initial data and clinical readouts for LP-184 on-track for the second half of 2024. Obtained regulatory allowance to begin Phase 2 Harmonic™ clinical trial enrollment in Japan and Taiwan where approximately 30-35+% ...
XCE853 is Oregon Therapeutic’s first-in-class, and potentially best-in-class PDI inhibitor, exhibiting potent preclinical efficacy across multiple solid and hematological cancers, and is ready to advance to Investigational New Drug (IND)-enabling development. The AI-enabled collabo...